Zhang Hui, Qi Hua-Zhao, Mao Jun, Zhang Hong-Rui, Luo Qing-Qing, Hu Mei-Ling, Shen Chen, Ding Lan
College of Life Science, Northwest Normal University, Lanzhou, Gansu 730070, PR China; State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan 610041, PR China.
College of Life Science, Northwest Normal University, Lanzhou, Gansu 730070, PR China.
Bioorg Chem. 2022 May;122:105722. doi: 10.1016/j.bioorg.2022.105722. Epub 2022 Mar 12.
Disruption of the dynamic equilibrium of microtubules can induce cell cycle arrest in G2/M phase and apoptosis. Hence, discovery of novel tubulin polymerization inhibitors is very necessary and an important task in drug research and development for treatment of various tumors. In this investigation, 50 compounds were screened as microtubule stabilizers targeting the taxane site by combination of molecular docking methods. Among these hits, hits 19 and 38 with novel scaffolds exhibited the highest anti-proliferative activity with IC ranging from 9.50 to 13.81 μM in four cancer cell lines. The molecular dynamics simulations confirmed that tubulin and two hits could form stable systems. Meanwhile, the mechanism of the interactions between tubulin and two hits at simulated physiological conditions were probed. The in vitro tubulin polymerization assay revealed hits 19 and 38 were able to promote tubulin polymerization in a dose-dependent manner. Further, the immunofluorescence assay suggested that hits 19 and 38 could accelerate microtubule assembly in A549 and HeLa cells. Finally, studies on antitumor activity indicated that hits 19 and 38 induced G2/M phase cell cycle arrest and apoptosis, and inhibited cancer cell motility and migration in A549 and HeLa cells. Importantly, hit38 exhibited better anti-tubulin and anti-cancer activity than hit19 in A549 and HeLa cells. Therefore, these results suggest that hit38 represents a promising microtubule stabilizer for treating cancer and deserves further investigation.
微管动态平衡的破坏可诱导细胞周期在G2/M期停滞并引发凋亡。因此,发现新型微管蛋白聚合抑制剂是非常必要的,也是治疗各种肿瘤药物研发中的一项重要任务。在本研究中,通过分子对接方法相结合,筛选出50种化合物作为靶向紫杉烷位点的微管稳定剂。在这些命中化合物中,具有新型骨架的命中化合物19和38在四种癌细胞系中表现出最高的抗增殖活性,IC值范围为9.50至13.81μM。分子动力学模拟证实微管蛋白与两种命中化合物可形成稳定系统。同时,探究了在模拟生理条件下微管蛋白与两种命中化合物之间相互作用的机制。体外微管蛋白聚合试验表明,命中化合物19和38能够以剂量依赖的方式促进微管蛋白聚合。此外,免疫荧光试验表明,命中化合物19和38可加速A549和HeLa细胞中的微管组装。最后,抗肿瘤活性研究表明,命中化合物19和38诱导A549和HeLa细胞的G2/M期细胞周期停滞和凋亡,并抑制癌细胞的运动和迁移。重要的是,在A549和HeLa细胞中,命中化合物38比命中化合物19表现出更好的抗微管蛋白和抗癌活性。因此,这些结果表明,命中化合物38是一种有前景的用于治疗癌症的微管稳定剂,值得进一步研究。